Compare ARCT & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | EARN |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 172.1M |
| IPO Year | 2019 | 2012 |
| Metric | ARCT | EARN |
|---|---|---|
| Price | $8.57 | $4.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $24.11 | $5.38 |
| AVG Volume (30 Days) | 315.4K | ★ 408.3K |
| Earning Date | 05-07-2026 | 06-16-2026 |
| Dividend Yield | N/A | ★ 20.51% |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | $12.77 | $19.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.85 | $4.27 |
| 52 Week High | $24.14 | $6.08 |
| Indicator | ARCT | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 54.35 |
| Support Level | $6.08 | $4.54 |
| Resistance Level | $8.97 | $4.77 |
| Average True Range (ATR) | 0.44 | 0.09 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 34.76 | 69.55 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.